[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

RSLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

ReShape Lifesciences Insider Trading History Chart

ReShape Lifesciences Share Price & Price History

^$5.55

▼ -0.03 (-0.54%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

ReShape Lifesciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/25/2023	Thomas Stankovich	CFO	Sell	2	$15.66	$31.32	395
10/11/2023	Thomas Stankovich	CFO	Sell	0	$53.94	$0.00	397
9/1/2023	Thomas Stankovich	CFO	Sell	2	$51.62	$103.24	398
8/24/2023	Thomas Stankovich	CFO	Sell	0	$82.36	$0.00	400
8/4/2023	Thomas Stankovich	CFO	Sell	1	$82.94	$82.94	401
7/6/2023	Thomas Stankovich	CFO	Sell	1	$85.26	$85.26	403
6/30/2023	Thomas Stankovich	CFO	Buy	305	$88.16	$26,888.80	405
5/31/2023	Thomas Stankovich	CFO	Sell	1	$139.78	$139.78	99
4/30/2023	Thomas Stankovich	CFO	Sell	1	$136.88	$136.88	101
3/31/2023	Thomas Stankovich	CFO	Sell	1	$150.80	$150.80	103
2/28/2023	Thomas Stankovich	CFO	Sell	1	$246.50	$246.50	105
2/2/2023	Thomas Stankovich	CFO	Sell	2	$770.82	$1,541.64	106
1/24/2023	Thomas Stankovich	CFO	Sell	2	$434.42	$868.84	109
11/4/2022	Thomas Stankovich	CFO	Sell	2	$783.00	$1,566.00	114
10/4/2022	Thomas Stankovich	CFO	Sell	2	$812.00	$1,624.00	116
9/6/2022	Thomas Stankovich	CFO	Sell	1	$1,131.00	$1,131.00	119
8/5/2022	Barton P. Bandy	CEO	Sell	4	$1,363.00	$5,452.00	266
8/5/2022	Thomas Stankovich	CFO	Sell	1	$1,363.00	$1,363.00	121
7/1/2022	Barton P. Bandy	CEO	Sell	3	$1,595.00	$4,785.00	270
7/1/2022	Thomas Stankovich	CFO	Sell	1	$1,595.00	$1,595.00	122
6/1/2022	Barton P. Bandy	CEO	Sell	3	$2,755.00	$8,265.00	274
5/31/2022	Thomas Stankovich	CFO	Buy	6	$2,668.00	$16,008.00	126
4/1/2022	Barton P. Bandy	CEO	Sell	3	$3,277.00	$9,831.00	282
4/1/2022	Thomas Stankovich	CFO	Sell	1	$3,277.00	$3,277.00	120
1/31/2022	Barton P. Bandy	CEO	Sell	2	$3,538.00	$7,076.00
1/31/2022	Thomas Stankovich	CFO	Sell	1	$3,538.00	$3,538.00
1/4/2022	Barton P. Bandy	CEO	Sell	2	$5,191.00	$10,382.00
1/4/2022	Thomas Stankovich	CFO	Sell	1	$5,162.00	$5,162.00
12/2/2021	Barton P. Bandy	CEO	Sell	4	$5,307.00	$21,228.00
12/2/2021	Thomas Stankovich	CFO	Sell	1	$5,307.00	$5,307.00

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

SEC Filings (Institutional Ownership Changes) for ReShape Lifesciences (NASDAQ:RSLS)

22.06% of ReShape Lifesciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ReShape Lifesciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	Armistice Capital LLC	188,000	$64K	0.0%	N/A	5.449%
5/11/2022	GSA Capital Partners LLP	36,490	$43K	0.0%	N/A	0.196%
11/15/2021	Sassicaia Capital Advisers LLC	10,000	$29K	0.1%	N/A	0.063%
8/17/2021	Armistice Capital LLC	816,527	$4.08M	0.1%	N/A	24.447%
8/16/2021	State Street Corp	109,999	$0.55M	0.0%	N/A	3.293%
8/13/2021	Alpine Global Management LLC	17,000	$85K	0.0%	N/A	0.509%
8/13/2021	Geode Capital Management LLC	23,277	$0.12M	0.0%	N/A	0.697%
8/13/2021	Vanguard Group Inc.	51,120	$0.26M	0.0%	N/A	1.531%

Data available starting January 2016

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Today's Range

Now: $5.55

$5.34

$5.88

50 Day Range

MA: $5.86

$4.95

$9.43

52 Week Range

Now: $5.55

$4.60

$34.22

Volume

30,581 shs

Average Volume

157,148 shs

Market Capitalization

$3.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Who are the company insiders with the largest holdings of ReShape Lifesciences?: ReShape Lifesciences' top insider shareholders include:
Thomas Stankovich (CFO)
Learn More about top insider investors at ReShape Lifesciences.